Specialized Focus Target metabolic disease CRO collaborations. ProSciento specializes in diabetes, obesity, and NAFLD/NASH, presenting a clear opportunity to position complementary services, biomarkers, and patient recruitment capabilities to expand depth in metabolic trials.

North America Core Profil operates as ProSciento’s clinical research unit in North America with metabolism-focused capabilities. Leverage existing regional footprint to upsell full-scope metabolic trial services, site expansion, and patient access programs.

Engaged Partnerships Active industry partnerships and ongoing involvement with Breakthrough T1D and ADA events indicate receptivity to collaboration and sponsor-led initiatives. Propose joint patient engagement, awareness campaigns, and sponsor-driven trial support packages.

Leadership Expansion Recent executive hires such as COO and VP of People signal organizational growth and focus on operations and talent. Leverage this momentum to offer scalable study management, site network optimization, and workforce-enabled trial execution services.

Innovation Recognition 2023 Innovation Award and metabolic disease leadership position the company as an innovator in liver and metabolic research. Present opportunities around novel trial designs, digital health integration, and precision medicine approaches to attract high-value studies.